Abstract
PURPOSE: Temsirolimus and pazopanib serve as first-line therapies for renal cell carcinoma (RCC). This meta-analysis was performed to assess and compare their efficacy, optimal treatment targets, and associated toxicities. METHODS: We searched the PubMed, CNKI, Wanfang, and VIP databases for relevant literature published from 2003 to 2023. Studies were selected based on specific exclusion criteria, and eligible articles were subjected to data extraction for subsequent subgroup analysis. RESULTS: Fourteen studies of moderate to high quality were included. In the low-risk group, the mortality rate was significantly lower in the temsirolimus group at 0.23 (95% Cl, 0.15-0.31) compared to 0.44 (95% Cl, 0.40-0.47) in the pazopanib group. In the high-risk group, the mortality rate was 0.73 (95% Cl, 0.69-0.76) for temsirolimus and 0.67 (95% Cl, 0.64-0.71) for pazopanib. CONCLUSION: Temsirolimus demonstrated greater efficacy in the low-risk group, while pazopanib was superior in the high-risk group for the treatment of RCC. Consideration of both efficacy and toxicity is crucial to guide drug selection for patients. TRN: CRD42024578497 (Registration date: 2024/08/21).